NorthRock Partners LLC Takes Position in DexCom, Inc. (NASDAQ:DXCM)

NorthRock Partners LLC acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 7,668 shares of the medical device company's stock, valued at approximately $596,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in DXCM. MayTech Global Investments LLC grew its stake in shares of DexCom by 8.3% in the 4th quarter. MayTech Global Investments LLC now owns 280,766 shares of the medical device company's stock valued at $21,835,000 after buying an additional 21,509 shares during the period. Meridiem Capital Partners LP acquired a new stake in shares of DexCom during the fourth quarter valued at about $32,158,000. LMR Partners LLP acquired a new stake in shares of DexCom during the fourth quarter valued at about $11,924,000. LRI Investments LLC increased its position in shares of DexCom by 17.2% during the fourth quarter. LRI Investments LLC now owns 9,910 shares of the medical device company's stock valued at $771,000 after acquiring an additional 1,456 shares during the last quarter. Finally, Laird Norton Wetherby Wealth Management LLC increased its position in shares of DexCom by 16.2% during the fourth quarter. Laird Norton Wetherby Wealth Management LLC now owns 7,456 shares of the medical device company's stock valued at $580,000 after acquiring an additional 1,040 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have weighed in on DXCM. Wells Fargo & Company reiterated an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Cfra Research upgraded shares of DexCom to a "hold" rating in a research report on Friday, March 21st. Robert W. Baird dropped their price target on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Barclays lifted their price objective on shares of DexCom from $90.00 to $93.00 and gave the company an "equal weight" rating in a report on Monday, May 5th. Finally, Mizuho initiated coverage on shares of DexCom in a report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price objective for the company. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, DexCom has an average rating of "Moderate Buy" and an average price target of $98.11.

Insider Transactions at DexCom

In other news, EVP Michael Jon Brown sold 13,000 shares of DexCom stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $914,940.00. Following the transaction, the executive vice president now directly owns 105,602 shares of the company's stock, valued at $7,432,268.76. The trade was a 10.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Jereme M. Sylvain sold 7,000 shares of DexCom stock in a transaction on Monday, March 10th. The shares were sold at an average price of $73.83, for a total transaction of $516,810.00. Following the completion of the transaction, the executive vice president now directly owns 135,482 shares in the company, valued at $10,002,636.06. The trade was a 4.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 66,926 shares of company stock worth $4,734,384. 0.32% of the stock is currently owned by insiders.

DexCom Stock Up 1.7%

DexCom stock traded up $1.48 during trading on Monday, reaching $86.96. The stock had a trading volume of 2,366,347 shares, compared to its average volume of 4,356,666. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $132.09. The business has a 50 day moving average price of $72.01 and a 200 day moving average price of $77.69. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The stock has a market cap of $34.10 billion, a PE ratio of 60.81, a P/E/G ratio of 2.30 and a beta of 1.43.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). The company had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a return on equity of 30.14% and a net margin of 14.29%. The firm's quarterly revenue was up 12.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.32 EPS. On average, analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.